Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role

Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status

First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC

Deeper Dive: A Plethora of Prediction Models

Lung Cancer Diagnosis and Staging During COVID-19

Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?

Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?

Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’

Liquid biopsy for early lung cancer detection and cancer interception

The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

IASLC Journals Share Exciting Milestones on Metrics Journeys